Answers are grounded in this paper and cite their sources.
It is clear that an important issue such as cell homeostasis must be controlled in a multicellular organism. However, as any other mechanism, the control of cell numbers can also be dysregulated under pathological conditions. For instance, inflammatory diseases are normally associated with an increase in the numbers of inflammatory cells. Therefore, allergologists have occupied themselves with trying to understand the marked accumulation of eosinophils associated with chronic allergic inflammation for many years. In this issue of Clinical and Experimental Allergy, Kodama et al. [ 1] report on the role of eosinophil apoptosis in vivo in a mouse model of eosinophilic inflammation. In this study, apoptotic eosinophils were identified using electron microscopy and a specific technique to identify DNA fragmentation, a hallmark of apoptotic cells. The data by Kodama et al. suggest that the resolution of eosinophilic inflammation is most likely the consequence of the induction of eosinophil apoptosis. These findings are not surprising since apoptosis is the most common form of physiological cell death. Moreover, the resolution of eosinophilic inflammation and its association with eosinophil apoptosis has been previously described in in vivo mouse [ 2] and human [ 3] systems. Taken together, the importance of apoptosis for the removal of eosinophils in vivo is now well established. Perhaps more exciting is the fact that apoptosis can be dysregulated and may then contribute to pathogenic processes. For instance, defective regulation of apoptosis may play a part in the aetiology of cancer, AIDS, autoimmune diseases, and neurodegenerative disorders [ 4, 5]. Interestingly, the process of eosinophil apoptosis is delayed in allergic inflammatory sites [ 6] and, perhaps, also in the blood [ 7] of atopic patients. Therefore, it appears that delayed apoptosis contributes to the accumulation of these cells in chronic allergic inflammation. The article by Kodama et al. [ 1] also provides evidence for a delayed apoptotic eosinophil death, although a direct demonstration has yet to be provided in their model of eosinophilic inflammation. In addition, the suggested delay of eosinophil death in the current study [ 1] does not appear to be as dramatic as observed in nasal polyp tissues [ 6]. The reason for this could be that the ovalbumin-sensitized and challenged mouse represents an acute inflammatory response and may not be the best model for studying chronic eosinophilic inflammation. Why is the mechanism of delayed eosinophil apoptosis important for the specific accumulation of this cell type in chronic allergic responses? Previously published work suggests that eosinophils specifically adhere to the endothelium and migrate into tissues with the help of eosinophil-specific chemoattractants. For instance, IL-4, an important cytokine in allergic responses, induces vascular cell adhesion molecule (VCAM)-1 in microvascular endothelial cells. VCAM-1 binds to cells bearing the integrin very late antigen (VLA)-4. The expression of VLA-4 by eosinophils, but not neutrophils, suggests that the VCAM-1/VLA-4 adhesion pathway contributes to the preferential migration of eosinophils into allergic inflammatory sites [ 8, 9]. However, eosinophilia have also been observed under conditions where IL-4 is not or barely expressed [ 6, 10]. On the other hand, mice over-expressing IL-4 in the lung demonstrated a cellular infiltrate consisting of macrophages, lymphocytes, eosinophils, and neutrophils [ 11]. Moreover, the intercellular adhesion molecule (ICAM)-1/integrin CD11/CD18 pathway appears to be equally important for eosinophils and neutrophils [ 12, 13], suggesting that IL-4-induced VCAM-1 expression alone cannot explain the accumulation of eosinophils in allergic inflammation. Another possibility to achieve selectivity in the migration of circulating leucocytes into tissues is the differential expression of receptors for chemoattractants. For instance, eotaxin has been reported to selectively stimulate eosinophils [ 14, 15], although recent reports suggest that eotaxin can also activate basophils [ 16] and possibly even T cells [ 17]. Eotaxin binds, like regulated upon activation normal T cells expressed and secreted (RANTES) and monocyte chemotactic protein (MCP)-4, to the chemokine receptor CCR3, which is expressed by eosinophils but not neutrophils, suggesting a possible specific recruitment pathway for eosinophils mediated by these chemokines. However, other chemoattractants present in allergic tissues, such as platelet-activating factor (PAF) [ 18], complement factors [ 19], leukotrienes [ 20], and IL-8 [ 21], act on both eosinophils and neutrophils. Therefore, it is unlikely that selective accumulation of eosinophils occurs exclusively at the level of chemotaxis. This view is strongly supported by observations in vivo. After antigen challenge, an increased initial, non-specifc recruitment of inflammatory cells, including neutrophils, has been reported in murine and human models [ 22, 23]. Thus, the story of how eosinophils accumulate in tissues appears to be more complicated than we have thought so far. Meanwhile, specific delayed eosinophil apoptosis was shown to play an important role for the development of tissue eosinophilia [ 6]. As discussed in more detail below, activated T cells express high levels of IL-5 that acts as a survival factor by inhibiting eosinophil but not neutrophil apoptosis. The data discussed here suggest that specific eosinophil accumulation in allergic tissues is achieved by a complex cascade of different events. In Fig. 1, we suggest a three-step model which considers the contribution of all mechanisms discussed above. According to this model, eosinophil expansion in tissues is regulated at the levels of adhesion, chemotaxis and apoptosis. Each step results in more selectivity for eosinophils. /VLA–4 molecular interactions result in relatively high binding of eosinophils compared to neutrophils (note that neutrophil numbers are usually higher than eosinophil numbers in blood). Subsequent migration into tissue is directed by chemotactic factors. Most of the chemotactic factors act on both neutrophils and eosinophils. In contrast, eotaxin appears to specifically attract eosinophils, resulting in further enrichment of eosinophils. In the absence of survival factors, neutrophils rapidly undergo apoptosis. At the same time, IL-5 prevents eosinophil apoptosis while further eosinophils are recruited, causing specific accumulation of eosinophils. How is delayed eosinophil apoptosis in allergic inflammatory responses achieved? Clearly, as mentioned above, over-production of survival factors such as IL-5 is one important mechanism. Therefore, IL-5-initiated intracellular signalling mechanisms that mediate anti-apoptosis in eosinophils have been investigated [ 2425262728]. Moreover, there is some progress in the identification of antiapoptotic genes. Whereas immature eosinophils express significant levels of Bcl-2 [ 29], it appears that Bcl-xL, but not Bcl-2, exerts an anti-apoptotic effect in mature eosinophils [ 30]. Recently published work suggests that eosinophil apoptosis is not only regulated by the presence or absence of survival factors. Eosinophils can be also triggered to die via surface death receptors. One of these death receptors expressed by eosinophils is CD95 (Fas/APO-1) [ 2, 313233]. The ligand of CD95 (CD95 L, FasL, APO-1 L) is highly expressed by activated T cells [ 34]. Thus, the same cells which produce eosinophil survival factors also express at least one death factor for eosinophils. Interestingly, activation of the CD95-mediated apoptotic pathway in eosinophils occurs even in the presence of eosinophil survival factors [ 2, 32]. Therefore, the newly discovered additional possibility to actively induce eosinophil apoptosis makes sense: CD95 L/CD95 molecular interactions may serve to limit eosinophil expansion independently from eosinophil haematopoietin expression within inflammatory sites. However, this story is less simple than first thought. There is at least one counter-regulatory mechanism that causes CD95 resistance in eosinophils: nitric oxide, a secretory product released in increased amounts within chronic eosinophilic inflammatory responses, disrupts CD95-induced signals in eosinophils [ 32]. Therefore, the phenomenon of CD95 resistance could be of pathophysiological relevance. In conclusion, as the current study by Kodama et al. also demonstrated [ 1], there is no doubt that eosinophils die in vivo due to apoptosis. Moreover, there is accumulating evidence that eosinophil apoptosis can be delayed in allergic disorders. There are at least two important mechanisms responsible for this phenomenon: increased expression of eosinophil survival factors, and disruption of death signals. The identification of molecules involved in the anti-apoptosis pathways in eosinophils offers hope for the development of new drugs that reduce eosinophil numbers, and, consequently, eosinophilic inflammation in allergic diseases [ 35]. The work of the author's laboratory is supported by the Swiss National Science Foundation (Grant number 32-49210.96).
No takes yet. Share an insight, caveat, or question.
Hans‐Uwe Simon (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: